[18F]FPenM-C2Am showed a favourable biodistribution profile with predominant renal clearance. In human xenograft models treated with a TRAIL-R2 agonist, [18F]FPenM-C2Am generated tumour-to-muscle and tumour-to-blood ratios of [6.7±0.8] and [9.3±2.3] respectively in a colorectal cancer model and [1.89±0.23] and [3.1±0.4] in a breast cancer model.
Given the favourable biodistribution, [18F]FPenM-C2Am has potential for clinical translation.
References
1. Neves AA et al. (2017), 'Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I', J Nucl Med. 58:881-887.